Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial

AIMS/HYPOTHESIS: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney disease, hospitalised heart failure or cardiovascular death, and death from all causes in patients with chronic kidney disease (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Waijer, Simke W., Vart, Priya, Cherney, David Z. I., Chertow, Glenn M., Jongs, Niels, Langkilde, Anna Maria, Mann, Johannes F. E., Mosenzon, Ofri, McMurray, John J. V., Rossing, Peter, Correa-Rotter, Ricardo, Stefansson, Bergur V., Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174107/
https://www.ncbi.nlm.nih.gov/pubmed/35445820
http://dx.doi.org/10.1007/s00125-022-05694-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174107/
https://www.ncbi.nlm.nih.gov/pubmed/35445820
http://dx.doi.org/10.1007/s00125-022-05694-6

Ejemplares similares